Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
Health Canada Health Products & Food Regulatory Modernization
Health Canada policies with respect to Subsequent Entry Biologics
Health Canada policies with respect to drug compounding and/or admixing
International Trade Canada's Invest in Canada policies and programs with respect to investment, business development and innovation in the life sciences industry sector
Patent Act as it relates to the regulation of intellectual property for therapeutic products
Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
Patented Medicine Prices Review Board with respect to regulations of reporting obligations of patentees
Patented Medicine Prices Review Board with respect to the regulation of pricing of patented drug products
Policies or programs with respect to Federal Public Drug Benefit Programs
Proposed and potential policies with respect to current or potential regulation of cross-border trade in pharmaceuticals, including the Export Control List
Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy
Regulation
Canadian Environmental Protection Act Regulations with regard to the regulation of chemicals and toxic substances, specifically Bisphenol A, Bis ( 2-ETHYLHEXYL) Phthalate, Benzyl Butyl Phthalate and Dibutyl Phthalate
Federal Chemicals Management Plan as it relates to the regulation of chemicals and toxic substances, specifically Bisphenol A, Bis ( 2-ETHYLHEXYL) Phthalate, Benzyl Butyl Phthalate and Dibutyl Phthalate
Food and Drug Regulations specifically with respect to approval, regulation and life-cycle management of therapeutic products
Food and Drug Regulations with respect to Data Protection under. C.08.004
Medical Devices Regulations under the Food and Drugs Act, specifically with respect to the approval, regulation and life cycle management of medical devices
Patent Act regulations as they relate to the regulation of intellectual property for therapeutic products and the Patented Medicines (Notice of Compliance) Regulations